Pharvaris N.V. filings document foreign private issuer disclosures for a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists. Form 6-K reports furnish financial results, business updates, investor presentations, clinical-study updates, annual general meeting voting results and materials incorporated by reference into Form F-3 and Form S-8 registration statements.
The filing record also covers capital-structure activity involving ordinary shares and pre-funded warrants, registration rights agreements, underwriting documents, share-based compensation and governance matters. These disclosures frame Pharvaris' development-stage operating expenses, financing activity, shareholder approvals and formal reporting obligations as a Nasdaq-listed foreign private issuer.
Pharvaris N.V. has called its annual general meeting for June 26, 2026 in Amsterdam and circulated the 2025 Dutch statutory annual accounts and board report. Shareholders will vote on adopting the 2025 accounts, appointing PricewaterhouseCoopers as 2026 auditor, renewing a share repurchase authorization of up to 10% of issued capital for 18 months, and re-appointing Dr. Margareta Elisabeth Björk as a non-executive director.
The company reiterates its focus on deucrictibant, an oral bradykinin B2 receptor antagonist for hereditary and acquired angioedema. A pivotal Phase 3 on-demand study (RAPIDe-3) met its primary and all key secondary endpoints, and Pharvaris plans to submit a New Drug Application in the first half of 2026. A global Phase 3 prophylaxis study (CHAPTER-3) of the extended-release tablet is ongoing with topline data anticipated in the third quarter of 2026, alongside the CREAATE Phase 3 program in acquired angioedema.
Pharvaris N.V. principal accounting officer Anna Nijdam sold 2,670 shares of common stock in an open-market transaction on June 4, 2026, at a weighted average price of about $30.87 per share. The shares sold were acquired upon vesting of restricted stock units, and she continues to hold 46,275 shares directly after the sale.
PHVS reporting under Rule 144: notices list proposed sales of Common Stock tied to restricted stock grants and two recent dispositions by Anna Nijdam. The filing shows restricted stock grant quantities of 1,578 (10/01/2021) and 1,092 (10/01/2022), and reported sales of 5,501 shares on 05/22/2026 for $169,084.24 and 1,829 shares on 05/21/2026 for $55,971.24.
Pharvaris N.V. director Viviane Monges sold 9,667 shares of Common Stock in an open-market transaction. The sale occurred on May 21, 2026 at a weighted average price of $30.2941 per share, with individual trade prices ranging from $30.08 to $30.49 per share.
The shares sold were previously acquired upon vesting of restricted stock units granted as equity compensation. Following this transaction, Monges directly holds 5,500 Pharvaris shares. A footnote also corrects prior beneficial ownership reported on a Form 3, which had understated holdings by 513 shares due to earlier administrative errors in tax-withholding records.
Pharvaris N.V. insider activity centers on an option exercise paired with share sales. Principal Accounting Officer Anna Nijdam exercised stock options to acquire 7,330 shares of Common Stock at $20.00 per share, then sold the same number of shares in open-market, cashless transactions on May 21–22, 2026 at weighted average prices around $30.60–$30.74 per share.
Following these transactions, she directly owns 48,945 Common Stock shares. The filing also corrects a prior RSU vesting report, clarifying that total beneficial ownership as of April 11, 2026 should have been 48,945 shares, five more than previously reported due to an overstated tax withholding amount.
Pharvaris N.V. CFO/CLO David W. Nassif reported an open-market sale of 10,000 shares of Common Stock at a weighted average price of $30.3076 per share. The shares sold were previously acquired upon vesting of restricted stock units. Following this transaction, he directly holds 120,300 shares. The filing also corrects a prior Form 3 that understated his beneficial ownership by 6,375 shares due to an administrative error in tax-withholding reporting.
Anna Nijdam filed a Form 144 notifying a proposed sale of 5,501 shares of Common Stock. The filing lists the sale date as 05/22/2026 and identifies the transaction as a stock option exercise with proceeds to be received in cash. The notice names Morgan Stanley Smith Barney LLC as broker. The filing also records 1,829 shares of Common Stock sold during the prior three months on 05/21/2026.
Pharvaris N.V. director Elisabeth Bjork executed a scheduled option exercise and share sale under a Rule 10b5-1 trading plan. She exercised stock options for 10,000 common shares at $8.05 per share in a cashless transaction and sold 10,000 common shares at a weighted average price of $29.3166, with individual sale prices ranging from $29.03 to $29.61. Following these transactions, she holds 15,167 common shares and 11,000 stock options, which expire on April 6, 2033. The option grant vested 25% on April 6, 2024, with the remaining shares vesting in equal monthly installments thereafter.
Pharvaris N.V. director and Chief Executive Officer Berndt Modig filed an amended Form 4 to update his reported shareholdings. The amendment adds previously omitted indirect holdings and does not change any transactions.
After this update, he is shown as holding 950,000 shares of Common Stock indirectly through Schoodic Management BV and 137,500 shares directly. The filing clarifies ownership totals rather than reporting new buys or sells.